tetano
Editor, Senior Moderator
Vaccine
. 2023 Jun 14;S0264-410X(23)00641-2.
doi: 10.1016/j.vaccine.2023.05.071. Online ahead of print. Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection
Deok-Hwan Kim[SUP] 1 [/SUP], Jiho Lee[SUP] 2 [/SUP], Sungsu Youk[SUP] 3 [/SUP], Jei-Hyun Jeong[SUP] 1 [/SUP], Da-Ye Lee[SUP] 4 [/SUP], Hyo-Seon Ju[SUP] 4 [/SUP], Ha-Na Youn[SUP] 4 [/SUP], Jin-Cheol Kim[SUP] 4 [/SUP], Soo-Bin Park[SUP] 4 [/SUP], Ji-Eun Park[SUP] 4 [/SUP], Ji-Yun Kim[SUP] 4 [/SUP], Tae-Hyeon Kim[SUP] 2 [/SUP], Seung-Hun Lee[SUP] 4 [/SUP], Hyukchae Lee[SUP] 2 [/SUP], Lah Mouhamed Abdallah Amal Abdal[SUP] 2 [/SUP], Dong-Hun Lee[SUP] 5 [/SUP], Pil-Gu Park[SUP] 6 [/SUP], Kee-Jong Hong[SUP] 6 [/SUP], Chang-Seon Song[SUP] 7 [/SUP]
Affiliations
Coronavirus disease 2019 (Covid-19) caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) became a pandemic, causing significant burden on public health worldwide. Although the timely development and production of mRNA and adenoviral vector vaccines against SARS-CoV-2 have been successful, issues still exist in vaccine platforms for wide use and production. With the potential for proliferative capability and heat stability, the Newcastle disease virus (NDV)-vectored vaccine is a highly economical and conceivable candidate for treating emerging diseases. In this study, a recombinant NDV-vectored vaccine expressing the spike (S) protein of SARS-CoV-2, rK148/beta-S, was developed and evaluated for its efficacy against SARS-CoV-2 in K18-hACE-2 transgenic mice. Intramuscular vaccination with low dose (10[SUP]6.0[/SUP] EID[SUB]50[/SUB]) conferred a survival rate of 76 % after lethal challenge of a SARS-CoV-2 beta (B.1.351) variant. When administered with a high dose (10[SUP]7.0[/SUP] EID[SUB]50[/SUB]), vaccinated mice exhibited 100 % survival rate and reduced lung viral load against both beta and delta variants (B.1.617.2). Together with the protective immunity, rK148/beta-S is an accessible and cost-effective SARS-CoV-2 vaccine.
Keywords: Intramuscular vaccine; K18-hACE-2 TG mice; Lung viral load; Newcastle disease virus-vectored vaccine; SARS-CoV-2.
. 2023 Jun 14;S0264-410X(23)00641-2.
doi: 10.1016/j.vaccine.2023.05.071. Online ahead of print. Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection
Deok-Hwan Kim[SUP] 1 [/SUP], Jiho Lee[SUP] 2 [/SUP], Sungsu Youk[SUP] 3 [/SUP], Jei-Hyun Jeong[SUP] 1 [/SUP], Da-Ye Lee[SUP] 4 [/SUP], Hyo-Seon Ju[SUP] 4 [/SUP], Ha-Na Youn[SUP] 4 [/SUP], Jin-Cheol Kim[SUP] 4 [/SUP], Soo-Bin Park[SUP] 4 [/SUP], Ji-Eun Park[SUP] 4 [/SUP], Ji-Yun Kim[SUP] 4 [/SUP], Tae-Hyeon Kim[SUP] 2 [/SUP], Seung-Hun Lee[SUP] 4 [/SUP], Hyukchae Lee[SUP] 2 [/SUP], Lah Mouhamed Abdallah Amal Abdal[SUP] 2 [/SUP], Dong-Hun Lee[SUP] 5 [/SUP], Pil-Gu Park[SUP] 6 [/SUP], Kee-Jong Hong[SUP] 6 [/SUP], Chang-Seon Song[SUP] 7 [/SUP]
Affiliations
- PMID: 37355454
- DOI: 10.1016/j.vaccine.2023.05.071
Coronavirus disease 2019 (Covid-19) caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) became a pandemic, causing significant burden on public health worldwide. Although the timely development and production of mRNA and adenoviral vector vaccines against SARS-CoV-2 have been successful, issues still exist in vaccine platforms for wide use and production. With the potential for proliferative capability and heat stability, the Newcastle disease virus (NDV)-vectored vaccine is a highly economical and conceivable candidate for treating emerging diseases. In this study, a recombinant NDV-vectored vaccine expressing the spike (S) protein of SARS-CoV-2, rK148/beta-S, was developed and evaluated for its efficacy against SARS-CoV-2 in K18-hACE-2 transgenic mice. Intramuscular vaccination with low dose (10[SUP]6.0[/SUP] EID[SUB]50[/SUB]) conferred a survival rate of 76 % after lethal challenge of a SARS-CoV-2 beta (B.1.351) variant. When administered with a high dose (10[SUP]7.0[/SUP] EID[SUB]50[/SUB]), vaccinated mice exhibited 100 % survival rate and reduced lung viral load against both beta and delta variants (B.1.617.2). Together with the protective immunity, rK148/beta-S is an accessible and cost-effective SARS-CoV-2 vaccine.
Keywords: Intramuscular vaccine; K18-hACE-2 TG mice; Lung viral load; Newcastle disease virus-vectored vaccine; SARS-CoV-2.